Compare Howmet Aerospace Inc (HWM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Howmet Aerospace (HWM) trades at $283.80, up 0.03% today, with a bullish technical signal and strong support at $279. The company reported Q2 2026 EPS of $1.33, beating estimates, and raised full-year guidance due to robust aerospace and defense demand. Revenue grew 24% year-over-year, with a net income margin of 20.52% and ROE of 34.89%.

Outlook is positive with 84% analyst buy ratings and a $334.63 consensus price target, implying 18% upside. Risks include high valuation multiples (P/E 60.63) and capital expenditure increases. Earnings momentum and institutional confidence support further growth, but investors should monitor execution on expanded capacity plans.

Regeneron Pharmaceuticals (REGN) trades at $794.71, down 1.65% on the day, with strong fundamentals including a P/E of 19.72 and net income margin of 27.86%. The stock is in a bullish technical trend, supported by moving averages, though RSI levels indicate overbought conditions. Recent quarterly EPS results have consistently beaten expectations, and the company maintains robust cash flow from operations of $4.98 billion in 2025. However, multiple class action lawsuits related to clinical trial disclosures present a near-term headwind.

The outlook remains positive due to earnings strength and analyst consensus, but legal risks and high valuation multiples warrant caution. Upside is supported by product growth in Eylea HD and Dupixent, while downside risks include litigation outcomes and potential regulatory scrutiny. The stock trades above the consensus price target of $756.93, suggesting limited near-term upside from current levels.